These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20886653)

  • 21. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone.
    Cowan RW; Singh G; Ghert M
    J Orthop Res; 2012 Jun; 30(6):877-84. PubMed ID: 22102368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A mouse model of luciferase-transfected stromal cells of giant cell tumor of bone.
    Lau CP; Wong KC; Huang L; Li G; Tsui SK; Kumta SM
    Connect Tissue Res; 2015 Nov; 56(6):493-503. PubMed ID: 26327464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression.
    Ng PK; Tsui SK; Lau CP; Wong CH; Wong WH; Huang L; Kumta SM
    J Cell Biochem; 2010 May; 110(2):438-46. PubMed ID: 20225273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.
    Nørgaard P; Law B; Joseph H; Page DL; Shyr Y; Mays D; Pietenpol JA; Kohl NE; Oliff A; Coffey RJ; Poulsen HS; Moses HL
    Clin Cancer Res; 1999 Jan; 5(1):35-42. PubMed ID: 9918200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
    Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells.
    van de Donk NW; Schotte D; Kamphuis MM; van Marion AM; van Kessel B; Bloem AC; Lokhorst HM
    Clin Cancer Res; 2003 Nov; 9(15):5735-48. PubMed ID: 14654559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.
    Viereck V; Emons G; Lauck V; Frosch KH; Blaschke S; Gründker C; Hofbauer LC
    Biochem Biophys Res Commun; 2002 Mar; 291(3):680-6. PubMed ID: 11855844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption.
    Lamoureux F; Richard P; Wittrant Y; Battaglia S; Pilet P; Trichet V; Blanchard F; Gouin F; Pitard B; Heymann D; Redini F
    Cancer Res; 2007 Aug; 67(15):7308-18. PubMed ID: 17671200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of type I collagen gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferase I.
    Rosenbloom J; Saitta B; Gaidarova S; Sandorfi N; Rosenbloom JC; Abrams WR; Hamilton AD; Sebti SM; Kucich U; Jimenez SA
    Arthritis Rheum; 2000 Jul; 43(7):1624-32. PubMed ID: 10902768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytochemical and ultrastructural changes in the osteoclast-like giant cells of giant cell tumor of bone following bisphosphonate administration.
    Cheng YY; Huang L; Kumta SM; Lee KM; Lai FM; Tam JS
    Ultrastruct Pathol; 2003; 27(6):385-91. PubMed ID: 14660277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
    Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis.
    Dan HC; Jiang K; Coppola D; Hamilton A; Nicosia SV; Sebti SM; Cheng JQ
    Oncogene; 2004 Jan; 23(3):706-15. PubMed ID: 14737105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
    Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
    Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of GGTase-I and FTase disrupts cytoskeletal organization of human PC-3 prostate cancer cells.
    Virtanen SS; Sandholm J; Yegutkin G; Kalervo Väänänen H; Härkönen PL
    Cell Biol Int; 2010 Aug; 34(8):815-26. PubMed ID: 20446922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
    Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
    J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter.
    Delarue FL; Adnane J; Joshi B; Blaskovich MA; Wang DA; Hawker J; Bizouarn F; Ohkanda J; Zhu K; Hamilton AD; Chellappan S; Sebti SM
    Oncogene; 2007 Feb; 26(5):633-40. PubMed ID: 16909123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.
    Du W; Prendergast GC
    Cancer Res; 1999 Nov; 59(21):5492-6. PubMed ID: 10554025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells.
    Miquel K; Pradines A; Sun J; Qian Y; Hamilton AD; Sebti SM; Favre G
    Cancer Res; 1997 May; 57(10):1846-50. PubMed ID: 9157972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A; Schulz H; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.